Literature DB >> 31990684

Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis.

Takashi Maehara1,2, Naoki Kaneko1,2, Cory A Perugino1,3, Hamid Mattoo1,4, Jesper Kers1,5,6,7, Hugues Allard-Chamard1,8, Vinay S Mahajan1,9, Hang Liu1,10, Samuel Jh Murphy1, Musie Ghebremichael1, David Fox11, Aimee S Payne12, Robert Lafyatis13, John H Stone3, Dinesh Khanna11, Shiv Pillai1.   

Abstract

Systemic sclerosis (SSc) is an autoimmune fibrotic disease whose pathogenesis is poorly understood and lacks effective therapies. We undertook quantitative analyses of T cell infiltrates in the skin of 35 untreated patients with early diffuse SSc and here show that CD4+ cytotoxic T cells and CD8+ T cells contribute prominently to these infiltrates. We also observed an accumulation of apoptotic cells in SSc tissues, suggesting that recurring cell death may contribute to tissue damage and remodeling in this fibrotic disease. HLA-DR-expressing endothelial cells were frequent targets of apoptosis in SSc, consistent with the prominent vasculopathy seen in patients with this disease. A circulating effector population of cytotoxic CD4+ T cells, which exhibited signatures of enhanced metabolic activity, was clonally expanded in patients with systemic sclerosis. These data suggest that cytotoxic T cells may induce the apoptotic death of endothelial and other cells in systemic sclerosis. Cell loss driven by immune cells may be followed by overly exuberant tissue repair processes that lead to fibrosis and tissue dysfunction.

Entities:  

Keywords:  Autoimmune diseases; Autoimmunity; Fibrosis; Immunology; T cells

Mesh:

Substances:

Year:  2020        PMID: 31990684      PMCID: PMC7190971          DOI: 10.1172/JCI131700

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.

Authors:  Muriel Elhai; Marouane Boubaya; Oliver Distler; Vanessa Smith; Marco Matucci-Cerinic; Juan José Alegre Sancho; Marie-Elise Truchetet; Yolanda Braun-Moscovici; Florenzo Iannone; Pavel I Novikov; Alain Lescoat; Elise Siegert; Ivan Castellví; Paolo Airó; Serena Vettori; Ellen De Langhe; Eric Hachulla; Anne Erler; Lidia Ananieva; Martin Krusche; F J López-Longo; Jörg H W Distler; Nicolas Hunzelmann; Anna-Maria Hoffmann-Vold; Valeria Riccieri; Vivien M Hsu; Maria R Pozzi; Codrina Ancuta; Edoardo Rosato; Carina Mihai; Masataka Kuwana; Lesley Ann Saketkoo; Carlo Chizzolini; Roger Hesselstrand; Susanne Ullman; Sule Yavuz; Simona Rednic; Cristian Caimmi; Coralie Bloch-Queyrat; Yannick Allanore
Journal:  Ann Rheum Dis       Date:  2019-04-09       Impact factor: 19.103

2.  Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells.

Authors:  Zsuzsanna H McMahan; Tricia R Cottrell; Fredrick M Wigley; Brendan Antiochos; Elias T Zambidis; Tea Soon Park; Marc K Halushka; Laura Gutierrez-Alamillo; Raffaello Cimbro; Antony Rosen; Livia Casciola-Rosen
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

3.  Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells.

Authors:  Lidia Bosurgi; Y Grace Cao; Mar Cabeza-Cabrerizo; Andrea Tucci; Lindsey D Hughes; Yong Kong; Jason S Weinstein; Paula Licona-Limon; Edward T Schmid; Facundo Pelorosso; Nicola Gagliani; Joseph E Craft; Richard A Flavell; Sourav Ghosh; Carla V Rothlin
Journal:  Science       Date:  2017-05-11       Impact factor: 47.728

Review 4.  Systemic sclerosis.

Authors:  Christopher P Denton; Dinesh Khanna
Journal:  Lancet       Date:  2017-04-13       Impact factor: 79.321

5.  Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis.

Authors:  Taher E Taher; Voon H Ong; Jonas Bystrom; Sophie Hillion; Quentin Simon; Christopher P Denton; Jacques-Olivier Pers; David J Abraham; Rizgar A Mageed
Journal:  Arthritis Rheumatol       Date:  2018-02-06       Impact factor: 10.995

6.  Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis.

Authors:  M C Vonk; Z Marjanovic; F H J van den Hoogen; S Zohar; A V M B Schattenberg; W E Fibbe; J Larghero; E Gluckman; F W M B Preijers; A P J van Dijk; J J Bax; P Roblot; P L C M van Riel; J M van Laar; D Farge
Journal:  Ann Rheum Dis       Date:  2007-05-25       Impact factor: 19.103

7.  Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.

Authors:  Patrizia Fuschiotti; Thomas A Medsger; Penelope A Morel
Journal:  Arthritis Rheum       Date:  2009-04

8.  Immunosenescent CD57+CD4+ T-cells accumulate and contribute to interferon-γ responses in HIV patients responding stably to ART.

Authors:  Sonia Fernandez; Martyn A French; Patricia Price
Journal:  Dis Markers       Date:  2011       Impact factor: 3.434

9.  Robust enumeration of cell subsets from tissue expression profiles.

Authors:  Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Methods       Date:  2015-03-30       Impact factor: 28.547

Review 10.  The role of type 1 interferon in systemic sclerosis.

Authors:  Minghua Wu; Shervin Assassi
Journal:  Front Immunol       Date:  2013-09-06       Impact factor: 7.561

View more
  34 in total

Review 1.  Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.

Authors:  Alain Lescoat; David Roofeh; Masataka Kuwana; Robert Lafyatis; Yannick Allanore; Dinesh Khanna
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-01       Impact factor: 10.817

Review 2.  The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis.

Authors:  Satomi Kobayashi; Yasuo Nagafuchi; Hirofumi Shoda; Keishi Fujio
Journal:  Front Immunol       Date:  2022-05-24       Impact factor: 8.786

3.  Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab.

Authors:  Jared Liu; Hsin-Wen Chang; Robby Grewal; Daniel D Cummins; Audrey Bui; Kristen M Beck; Sahil Sekhon; Di Yan; Zhi-Ming Huang; Timothy H Schmidt; Eric J Yang; Isabelle M Sanchez; Mio Nakamura; Shrishti Bhattarai; Quinn Thibodeaux; Richard Ahn; Mariela Pauli; Tina Bhutani; Michael D Rosenblum; Wilson Liao
Journal:  JID Innov       Date:  2021-12-30

Review 4.  Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.

Authors:  David Roofeh; Alain Lescoat; Dinesh Khanna
Journal:  Expert Opin Emerg Drugs       Date:  2020-10-26       Impact factor: 4.191

5.  Mer tyrosine kinase as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease.

Authors:  Lucrezia Rovati; Naoki Kaneko; Federica Pedica; Antonella Monno; Takashi Maehara; Cory Perugino; Marco Lanzillotta; Simone Pecetta; John H Stone; Claudio Doglioni; Angelo A Manfredi; Shiv Pillai; Emanuel Della-Torre
Journal:  Rheumatology (Oxford)       Date:  2021-10-02       Impact factor: 7.580

6.  CD4+CTLs in Fibrosing Mediastinitis Linked to Histoplasma capsulatum.

Authors:  Hugues Allard-Chamard; Faisal Alsufyani; Naoki Kaneko; Kelly Xing; Cory Perugino; Vinay S Mahajan; Joseph L Wheat; George S Deepe; James Loyd; Shiv Pillai
Journal:  J Immunol       Date:  2020-12-16       Impact factor: 5.422

7.  Single-cell transcriptome profiling reveals vascular endothelial cell heterogeneity in human skin.

Authors:  Qingyang Li; Zhenlai Zhu; Lei Wang; Yiting Lin; Hui Fang; Jie Lei; Tianyu Cao; Gang Wang; Erle Dang
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

Review 8.  New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

Authors:  Alain Lescoat; John Varga; Marco Matucci-Cerinic; Dinesh Khanna
Journal:  Expert Opin Investig Drugs       Date:  2021-05-13       Impact factor: 6.498

9.  Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.

Authors:  Roberto Lande; Anna Mennella; Raffaella Palazzo; Immacolata Pietraforte; Katia Stefanantoni; Nicoletta Iannace; Alessia Butera; Monica Boirivant; Roberta Pica; Curdin Conrad; Carlo Chizzolini; Valeria Riccieri; Loredana Frasca
Journal:  Int J Mol Sci       Date:  2020-07-19       Impact factor: 5.923

Review 10.  Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions.

Authors:  Hamid Mattoo; Shiv Pillai
Journal:  Cell Mol Life Sci       Date:  2021-06-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.